France’s Venipharm has announced the approval through the European decentralized procedure (DCP) of its biosimilar enoxaparin.
“This achievement is the result of a successful co-development with Nanjing King-Friend Biochemical Pharmaceutical,” Venipharm pointed out, describing the Chinese company